- Products and Services
- Science & Technology
Next-generation sequencing (NGS) is a trusted and powerful method for detecting multiple biomarkers with a single workflow. But not all NGS assays perform the same, and it can be challenging to find the best test to fit the needs of your clinical development program.
Large “pan-cancer” approaches can cover hundreds of biomarkers, making them powerful for early discovery; however, they lack optimization for specific intended uses and negatively impact overall data quality. Ultimately, this can slow patient identification and enrollment.
Rapid Custom SafeSEQ is the more sensitive, targeted, and tailored alternative to ensure you have access to the right test with the performance to provide the right information, at the right time.
Rapid Custom SafeSEQ provides you with custom ctDNA detection capabilities, designed to optimize biomarker performance, development, and accelerate clinical evaluations.
Accelerate your clinical study with our expert molecular design capabilities, focused on the most relevant therapeutic targets and emerging resistance mutations
Maximize ctDNA analysis with limits of detection (LoD) 0.03-0.06%, an order of magnitude more sensitive than pan-cancer plasma NGS panels
Elevate data quality and streamline testing, providing deeper insights into therapeutic response, emerging resistance and minimal/measurable residual disease (MRD)
Advance through clinical development with full diagnostic support, from IND through NDA, leveraging our proprietary platform
Sequencing power can be spread broadly across many genomic regions or focused on defined, clinically relevant regions. And while pan-cancer assays’ breadth is tremendously powerful for biomarker discovery, SafeSEQ focuses on only clinically-relevant targets to achieve best-in-class LoD.
Advancing clinical oncology programs also demands flexibility. Rapid Custom SafeSEQ keeps pace with an ever-changing biomarker landscape by ensuring test performance is optimized, even when panels change.
By maintaining the right balance of coverage and sensitivity, SafeSEQ maximizes and expedites patient enrollment and delivers deeper insights into biomarker validity
As the first provider of centralized ctDNA testing through our OncoBEAM technology, we understand how difficult it is to detect rare tumor-derived mutant molecules and how essential ultra-high sensitivity testing is to ensure accurate clinical measurement of ctDNA alterations.
Now, we are helping to solve even more clinical development challenges across the oncology spectrum, with SafeSEQ’s unparalleled performance.
Rapid Custom SafeSEQ panels are available as an RUO service as quickly as 4 weeks after design finalization.
We offer experienced regulatory guidance to help you define the optimum strategy for diagnostic support for your clinical development program.
Get started planning your custom SafeSEQ panel. Our ctDNA molecular diagnostics experts can quickly assess your specific requirements and provide a range of options to support your success.